The Federal Discount Nobody Told You About: Inside the 340B Program and Why Its Savings Rarely Reach Patients

A Program Built on Good Intentions

In 1992, Congress enacted Section 340B of the Public Health Service Act with a straightforward goal: require pharmaceutical manufacturers to sell medications at significantly reduced prices — sometimes 25 to 50 percent below wholesale — to certain federally designated healthcare providers. The logic was simple. Hospitals and clinics serving low-income, uninsured, and underserved populations bear disproportionate financial burdens. Cheaper drugs would help those institutions stretch their resources further and, in turn, extend more affordable care to the patients who needed it most.

Three decades later, the 340B program has grown into one of the largest drug discount mechanisms in the United States, covering more than 50,000 registered sites and generating an estimated $44 billion in discounts annually. Yet a persistent and uncomfortable question has emerged: where is all that money actually going?

How the Program Is Supposed to Work

Eligible entities — formally called "covered entities" — include disproportionate share hospitals (facilities treating high volumes of Medicaid and uninsured patients), federally qualified health centers, Ryan White HIV/AIDS clinics, children's hospitals, and several other categories of safety-net providers. Once registered, these organizations can purchase qualifying drugs at 340B ceiling prices, which are capped by a statutory formula tied to average manufacturer prices.

The savings generated are meant to subsidize the broader mission of serving underserved communities. A rural health clinic, for example, might use 340B proceeds to fund a diabetes education program, hire additional staff, or reduce copayments for uninsured patients. The program imposes no direct mandate on how covered entities must deploy savings — a design choice that, critics argue, has become the program's central weakness.

The Institutional Capture Problem

Over the past decade, hospital systems have expanded their 340B eligibility aggressively, registering off-site outpatient clinics, pharmacies, and specialty facilities at a pace that has prompted significant regulatory scrutiny. Because a hospital qualifies based on its overall Medicaid patient volume — not the volume at any specific site — a large health system can extend 340B purchasing privileges to facilities that serve relatively affluent, well-insured populations.

The financial incentive is considerable. A hospital purchases a drug at the 340B discounted price, then bills a commercial insurer or Medicare at the full reimbursement rate. The spread between those two figures — sometimes called the "340B margin" — flows directly to the institution. According to analyses published by the Health Affairs journal and the Medicare Payment Advisory Commission (MedPAC), many covered entities retain a substantial portion of this margin as operating revenue rather than directing it toward patient assistance.

A 2021 report from the Government Accountability Office found that covered entities rarely track whether 340B savings translate into reduced patient costs, and the Health Resources and Services Administration (HRSA), which oversees the program, lacks the statutory authority to mandate specific patient benefit requirements.

What Patients Are Supposed to Receive — and Often Don't

For an individual navigating the American healthcare system, the 340B program can feel entirely invisible. Unlike a manufacturer coupon or a pharmacy discount card, there is no mechanism by which a patient is automatically informed that the facility treating them participates in 340B, nor any guarantee that participation reduces their out-of-pocket costs.

Some covered entities do pass savings directly to patients through sliding-scale fees, reduced copayments, or free medication programs. Federally qualified health centers (FQHCs), in particular, are generally regarded as more faithful stewards of 340B savings, given their existing mandate to serve patients on an income-based sliding scale. However, hospital systems operating under far less restrictive community benefit obligations have drawn the sharpest criticism.

Patients prescribed specialty medications — oncology drugs, biologics, HIV antiretrovirals — are especially affected. These are precisely the high-cost therapies where 340B discounts are most substantial, and where the gap between institutional savings and patient benefit is most glaring.

The Oversight Gap and Recent Reform Efforts

HRSA conducts audits of covered entities, but the agency's enforcement capacity has long been described as inadequate relative to the program's scale. Covered entities are required to avoid duplicate discounts and diversion — meaning they cannot claim both 340B pricing and Medicaid rebates for the same drug, and they cannot dispense 340B drugs to ineligible patients. But beyond those compliance requirements, the program imposes no enforceable standard for how savings must benefit patients.

Pharmaceutical manufacturers have responded to this ambiguity with their own controversial countermeasures. Beginning around 2020, several major drug companies began restricting 340B pricing to in-house hospital pharmacies, refusing to honor the discounts at contract pharmacies — third-party retail pharmacies that covered entities partner with to dispense 340B drugs. Litigation over this practice has wound through federal courts, with inconsistent outcomes across different circuits.

Legislative proposals to reform 340B have circulated in Congress for years. Some advocates push for mandatory patient benefit requirements — rules that would compel covered entities to document and report how savings are used. Industry groups representing hospitals have largely opposed such mandates, arguing they would create administrative burdens without improving patient outcomes.

What You Can Do as a Patient

If you receive care at a federally qualified health center, community health center, or safety-net hospital, it is worth asking directly whether the facility participates in 340B and whether that participation affects your medication costs. Many FQHCs maintain in-house pharmacies where 340B pricing is applied transparently, and staff can often direct you to patient assistance resources funded in part by program savings.

HRSA maintains a public database of covered entities, searchable by state and zip code, at hrsa.gov. Identifying 340B-covered providers in your area and specifically seeking care there — particularly for high-cost prescriptions — is one of the few ways a patient can attempt to access program benefits proactively.

For those managing ongoing prescription costs outside of covered entity settings, the broader landscape of discount options — manufacturer assistance programs, generic substitution, mail-order pharmacies, and licensed online dispensaries — remains relevant. Understanding every available mechanism, including imperfect federal programs like 340B, is part of building a sustainable medication cost strategy.

A Program Worth Preserving — If Properly Enforced

The 340B program addresses a genuine and serious problem: the cost of medications in the United States is, by any international comparison, extraordinarily high, and that burden falls most heavily on those with the least capacity to absorb it. The program's underlying architecture is sound. Its execution, however, has drifted substantially from its original mandate.

For patients, the practical takeaway is one of cautious awareness. The discounts exist. The infrastructure to deliver them exists. What remains inconsistent is the institutional will — and the regulatory authority — to ensure those savings complete their intended journey from manufacturer to patient.